New hope for Hard-to-Treat tumors: targeted drug HRS-6719 enters human trials
NCT ID NCT06922357
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called HRS-6719 in people with advanced solid tumors that lack a gene called MTAP. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 120 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-6719
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have a specific genetic marker (MTAP deficiency).
What could go wrong
This is an early-phase trial with only 120 participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150081, China
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact